Stocktoria
BGM Group Ltd. BGM
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-01-12
BGM Group Ltd. financials (annual, from 10-K)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $25.1M | $46.5M | $64.9M | $57.1M | $50.0M |
| Gross profit | $4.1M | $1.8M | $6.2M | $5.6M | $7.5M |
| R&D expense | $1.4M | $568,470 | $1.2M | $8,000 | $54,000 |
| SG&A expense | — | — | $4.1M | $3.3M | $2.7M |
| Operating income | -$563,771 | -$2.6M | $2.1M | $2.4M | $4.8M |
| Interest expense | — | — | — | $57,671 | $242,877 |
| Income tax | -$619,981 | $219,166 | $194,302 | $255,133 | $864,908 |
| Net income | -$1.4M | -$7.8M | $1.1M | $3.2M | $5.1M |
| EPS (diluted) | $-0.20 | $-1.08 | $0.15 | $0.09 | $0.17 |
| Operating cash flow | $544,238 | $312,209 | $12.7M | $345,034 | $5.1M |
| Free cash flow | $304,105 | $132,450 | $10.6M | -$1.1M | $4.6M |
| Cash & equivalents | $9.8M | $7.5M | $14.3M | $10.5M | $11.9M |
| Inventory | $5.0M | $5.0M | $8.9M | $12.5M | $12.0M |
| Total assets | $53.0M | $51.3M | $64.5M | $75.4M | $48.1M |
| Total liabilities | $8.9M | $6.9M | $9.6M | $18.7M | $19.3M |
| Shareholders' equity | $44.1M | $44.4M | $55.0M | $56.7M | $28.8M |
Source: SEC EDGAR filings · CIK 0001779578 · as of 2024-09-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.